 |
| Issue 10, 31st July 2007
|
Dear Shareholders
Welcome to the latest edition of Apollo Life, our regular newsletter to keep shareholders informed about our latest developments.
If you would like any further information, please contact us.
Regards
John Priest - CEO |
|
|
|
 |
Apollo’s trial success - needle-free drug delivery
Apollo has had positive results from independent trials of its transdermal (across the skin) drug delivery technology, Intradel™.
Apollo CEO John Priest said Intradel™ is a breakthrough in the delivery of large water-soluble molecules across the dermis (skin) into sub-dermal and muscle layers – without the use of needles. |
|
|
|
Apollo strengthens its focus on drug development and trials
With the announcement that Dr Michael Luke has been appointed as Apollo’s Head of Drug Development, the company has confirmed its push to aggressively develop its clinical programs, including the future development of Oradel™ and Intradel™ drug delivery technologies. |
|
Apollo’s human expressed protein is in demand
Apollo is seeing strong growth in customers of its human expressed proteins, with a massive 680 per cent increase in the last quarter.
Of even greater importance is the fact that – of Apollo’s first-time customers, 91 per cent are returning to do repeat business, according to Leanne Daly, President of Sales and Marketing. |
|
| Click here to subscribe |
 |
| www.apollolifesciences.com |